Financial Data and Key Metrics Changes - The company reported third-quarter sales of $143 million, an increase of 8% from $132 million in the same quarter of 2024 [4] - Adjusted diluted EPS for the third quarter was $0.60, down from $0.61 in the same period last year, primarily due to unfavorable impacts from recent U.S. tax legislation [5][17] - Adjusted gross margin improved to 38.9%, up 66 basis points year-over-year [16][17] - Operating cash flow for the third quarter was $29 million, compared to $35 million in the same quarter of 2024 [18] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 22% year-over-year, accounting for 59% of overall company revenue, up from 52% in the previous year [4][5] - Medical end market sales rose by 22% compared to the same period in 2024, with bookings up 8% [5][7] - Aerospace and defense sales increased by 23% year-over-year [7] - Transportation sales decreased by 7% from the same period last year, attributed to softness in commercial vehicle products [9][10] Market Data and Key Metrics Changes - The book-to-bill ratio for the third quarter was slightly above 1, compared to marginally below 1 in the same quarter of 2024 [4] - Industrial and distribution sales showed a 9% sequential increase and a 21% year-over-year increase, indicating a steady recovery [9][46] - The North American light vehicle market is expected to be in the 15 million unit range, with European production forecasted at 16 million units and China at 30 million units [12] Company Strategy and Development Direction - The company aims to transition from a component supplier to a supplier of sensors, transducers, and subsystems, as validated by recent naval defense contract awards [8] - The focus remains on strong cash generation, appropriate capital allocation, and supporting organic growth and strategic acquisitions [18][19] - The company is monitoring the tariff and geopolitical environment while adapting to cost and price adjustments [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for medical, aerospace, and defense markets, despite mixed signals from the transportation sector [24][46] - The company anticipates continued strength in therapeutic products, with expectations for increased volumes in 2026 [7][11] - The adverse tax impact from recent U.S. tax legislation is expected to persist into 2026, with a projected tax rate in the low 20% range [35][36] Other Important Information - SideQuest revenues increased to $8.8 million in the third quarter, with bookings up 29% year-over-year [8][16] - The company repurchased 400,000 shares for approximately $17 million during the quarter, returning a total of $44 million to shareholders through dividends and buybacks year-to-date [18] Q&A Session Summary Question: Guidance on revenue and EPS - Management raised the midpoint on revenue guidance but lowered the midpoint on EPS guidance due to tax impacts and mixed market signals [22][23] Question: Transportation customers' production rates for 2026 - The transportation market is mixed, with some OEMs optimistic and others cautious, but solid bookings were noted [24] Question: Gross margin contribution by end markets - Margins are good across diversified end markets, with transportation trailing behind [25][26] Question: Tax impact in 2026 - The adverse tax impact from U.S. tax legislation is expected to continue, with a similar tax rate projected for 2026 [35][36] Question: Inventory levels in transportation - Days of supply for light vehicles are around 50 days, which is considered normal, with no immediate concerns [38] Question: SideQuest revenue contribution - Revenue from SideQuest is expected to show seasonality, with a step-up in revenues anticipated [39] Question: Operating expenses increase - The increase in operating expenses is primarily due to a $4.2 million reserve increase and higher equity-based compensation [40]

Financial Data and Key Metrics Changes - The company reported sales of $143 million for Q3 2025, an increase of 8% from $132 million in Q3 2024 [4] - Adjusted diluted EPS for Q3 2025 was $0.60, down from $0.61 in Q3 2024, primarily due to unfavorable impacts from recent U.S. tax legislation [5][16] - Adjusted gross margin improved to 38.9%, up 66 basis points year-over-year [15] - Operating cash flow for Q3 2025 was $29 million, compared to $35 million in Q3 2024 [17] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 22% year-over-year, accounting for 59% of overall company revenue [4][5] - Transportation sales decreased by 7% compared to the same period last year, totaling $58.5 million [10] - SideQuest revenues rose to $8.8 million, with bookings up 29% from the prior year [8][15] Market Data and Key Metrics Changes - Aerospace and defense sales increased by 23% year-over-year [7] - Medical end market sales were up 22% compared to Q3 2024, with bookings increasing by 8% [5][6] - Industrial market sales improved by 21% year-over-year, with a 9% sequential increase [9] Company Strategy and Development Direction - The company aims to transition from a component supplier to a supplier of sensors, transducers, and subsystems, as evidenced by recent naval defense contract awards [8] - The focus remains on strong cash generation, appropriate capital allocation, and supporting organic growth and strategic acquisitions [17] - The company is monitoring the tariff environment and adapting to cost and price adjustments in collaboration with customers and suppliers [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for medical, aerospace, and defense markets, despite mixed signals from the transportation sector [25][48] - The company anticipates continued strength in therapeutic products, while diagnostic ultrasound demand remains soft [11][50] - Future revenue guidance was narrowed to a range of $535 to $545 million, with adjusted diluted EPS expected between $2.20 and $2.25 [14] Other Important Information - The company repurchased 400,000 shares for approximately $17 million during the quarter, returning a total of $44 million to shareholders through dividends and buybacks year-to-date [17] - The balance sheet remains strong with a cash balance of $110 million and long-term debt of $91 million [17] Q&A Session Summary Question: Guidance on revenue and EPS - Management raised the midpoint of revenue guidance while lowering EPS guidance due to tax impacts and mixed market signals [22][24] Question: Transportation customers' production rates for 2026 - The transportation market outlook is mixed, with some OEMs optimistic and others cautious, but solid bookings were noted [25] Question: Gross margin contribution by end markets - Margins are good across diversified end markets, with medical, industrial, aerospace, and defense performing well, while transportation lags [26][27] Question: Tax impact in 2026 - The adverse tax impact from U.S. legislation is expected to continue into 2026, with a projected tax rate in the low 20% range [37][38] Question: SideQuest revenue contribution - SideQuest is expected to show seasonal revenue patterns, with a positive outlook for future awards and revenue growth [42] Question: Operating expenses increase - The increase in operating expenses is primarily due to a $4.2 million reserve increase and higher equity-based compensation [43]

Financial Data and Key Metrics Changes - Company reported first quarter sales of $126 million, essentially flat compared to the first quarter of 2024 [5][20] - Adjusted diluted earnings were $0.44 per share, down from $0.47 per share in the same period last year [22][23] - Adjusted gross margin was 37%, up 77 basis points year-over-year [21] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 14% year-over-year, accounting for 53% of overall revenue [5][6] - Medical end market sales rose by 13% compared to the same period in 2024, with a book to bill ratio of 1.3 [6][8] - Aerospace and Defense sales surged by 39% year-over-year, with bookings up 32% [9][10] - Industrial market sales increased by 4% year-over-year, with bookings up 19% [11][12] - Transportation sales decreased by 12% due to market dynamics in China [13][20] Market Data and Key Metrics Changes - Current bookings for the second quarter indicate an improving trend, but there is caution regarding second half demand due to tariffs and geopolitical uncertainty [4][19] - North American light vehicle market is expected to be in the 15 million to 16 million unit range, with potential impacts from tariffs [16][17] Company Strategy and Development Direction - Company is focused on diversification across medical, industrial, aerospace, and defense markets, while progressing in electrification and transportation [3][15] - The strategy includes moving from a component supplier to a supplier of sensors, transducers, and subsystems [10] - Company aims to expand its customer base and range of applications in diversified end markets [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term prospects despite near-term tariffs and economic pressures [19][69] - Demand in the medical end market is expected to remain solid, driven by ultrasound and therapeutic volume growth [15] - Aerospace and Defense revenue is anticipated to remain strong due to a healthy backlog and the SideQuest acquisition [15][18] Other Important Information - The company generated $16 million in operating cash flow for the first quarter, with a cash balance of $90 million [23][24] - Long-term debt balance was $87 million, providing good liquidity for strategic acquisitions [24] Q&A Session Summary Question: Booking profile strength in non-transportation business - Management noted strong bookings in diversified markets, particularly in medical therapeutics, but did not observe broad-based pre-buying [29][32] Question: Changes in transportation market assumptions - Management continues to monitor the transportation market but has not factored in any demand drop in guidance [33] Question: Guidance on profit profile for the year - Management indicated an increasing revenue profile throughout the year, supported by SideQuest seasonality and a mix change in diversified markets [34][35] Question: Manufacturing footprint and tariffs - Company has a regional manufacturing footprint with minimal imports from Asia, and is actively discussing pricing strategies with customers [39][41] Question: Margin improvement drivers - Expected margin enhancement is driven by growth in diversified markets, operational efficiency improvements, and currency impacts [64]

Financial Data and Key Metrics Changes - The company reported first quarter sales of $126 million, essentially flat compared to the first quarter of 2024 [4] - Adjusted diluted earnings were $0.44 per share, down from $0.47 per share in the same period last year [21] - The adjusted gross margin was 37%, up 77 basis points year-over-year [20] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 14% year-over-year, accounting for 53% of overall company revenue [4][5] - Medical end market sales rose by 13% compared to the same period in 2024, with a book to bill ratio of 1.3 [5][6] - Aerospace and Defense sales surged by 39% year-over-year, with bookings up 32% [8][9] - Industrial market sales increased by 4% year-over-year, with bookings up 19% [10][11] - Transportation sales decreased by approximately 12% due to market dynamics in China [12] Market Data and Key Metrics Changes - Current bookings for the second quarter indicate an improving trend, although there is caution regarding second half demand due to tariffs and geopolitical uncertainty [3][18] - North American light vehicle market is expected to be in the 15 million to 16 million unit range, with potential impacts from tariffs [15][16] - European production is forecasted at 16 million units, showing some softness due to overcapacity from Chinese OEMs [16] Company Strategy and Development Direction - The company continues to execute on its diversification strategy across medical, industrial, aerospace, and defense markets [2] - There is a focus on moving from a component supplier to a supplier of sensors, transducers, and subsystems [9] - The company aims to expand its customer base and range of applications in diversified end markets [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term prospects for the medical end market, driven by ultrasound and therapeutic volume growth [14] - The company is closely monitoring the impact of tariffs and geopolitical factors on demand [18] - There is an expectation of gradual recovery in the industrial market, although potential demand softening is being watched [11] Other Important Information - The company generated $16 million in operating cash flow for the first quarter, with a cash balance of $90 million at the end of the quarter [22][23] - The long-term debt balance was $87 million, providing good liquidity for strategic acquisitions [23] Q&A Session Summary Question: Booking profile strength in non-transportation business - Management noted strong bookings in diversified markets, particularly in medical therapeutics, but did not observe broad-based pre-buying [28][31] Question: Changes in transportation market assumptions - Management continues to monitor the transportation market but has not factored in any demand drop in their guidance [32] Question: Guidance on profit profile for the year - Management indicated that revenue is expected to increase throughout the year, aided by SideQuest seasonality and a favorable mix change [33][34] Question: Manufacturing footprint and tariffs - The company has a regional manufacturing footprint that mitigates tariff impacts, with a focus on adapting costs and pricing in collaboration with customers [38][40] Question: Margin improvement drivers - Expected drivers of margin improvement include growth in diversified markets and operational efficiency [64]